Europe follows USA in approving Sotyktu

Bristol Myers Squibb’s (NYSE: BMY) Sotyktu (deucravacitinib) is continuing to vindicate the company’s decision to favor the drug’s development over Otezla (apremilast).

BMS acquired Sotyktu in its acquisition of Celgene in 2019 for $74 million, and opted to keep it rather than already-approved Otezla which, because of competition issues, was sold on to Amgen (Nasdaq: AMGN) for $13.4 billion.

"The first once-daily oral option to provide significant symptom relief"Sotyktu has since won approval in the USA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.